CTRI/2023/05/053058
Completed
未知
A study to evaluate the ophthalmologic safety of the hydrating mist in healthy female subjects after daily use (3 days).
DPKA Universal Consumer Ventures Private Limited0 sites33 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- DPKA Universal Consumer Ventures Private Limited
- Enrollment
- 33
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Female healthy adult subjects with age 18\-45 years
- •2\.Subject is in good health condition.
- •3\.Subjects willing to refrain from use of other similar products during the study.
Exclusion Criteria
- •1\.Female with age less than 18 or more than 45 years of age
- •2\.Pregnant/lactating mothers
- •3\.Subjects with eye infection and sensitive eyes
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Safety checking of Product on eyesCTRI/2023/03/050979DPKA UNIVERSAL CONSUMER VENTURES PRIVATE LIMITED33
Not yet recruiting
Not Applicable
Evaluation of eye safety of test productCTRI/2022/07/043782ONESTO LABS PVT LTD
Not yet recruiting
Not Applicable
Assessment of Ophthalmological safety of skin care productCTRI/2023/11/059530DPKA UNIVERSAL CONSUMER VENTURES PRIVATE LIMITED
Unknown
Not Applicable
Clinical study about the ocular administration of the anti-VEGF antibody for the retinopathy of prematurityJPRN-UMIN000025361ara Medical University20
Completed
Phase 3
To assess the ability of retina specialists to successfully administer Aflibercept in eye.Health Condition 1: H36- Retinal disorders in diseases classified elsewhereCTRI/2023/10/059113Biosimilar collaborations Ireland Limited35